News
Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...
Novo Nordisk A/S ousted Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker struggles with growing competition ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback